Introduction {#sec1-1}
============

Ampullary Carcinoma emerges from the ampulla of vater complex which lies distal to the ramification of the pancreatic duct and the distal common bile duct. Ampullary Carcinoma roughly constitutes 7 percent of peri-ampullary tumors.^[@ref1]^ Although Ampullary Carcinoma belongs to the subset of peri-ampullary tumors, it is crucial to distinguish Ampullary Carcinoma against a broader group of peri-ampullary tumors because of the treatment and prognostic implications. For example, Primary Ampullary Carcinoma has a better prognosis when compared to other periampullary tumors like pancreatic cancer or extrahepatic cholangiocarcinoma. ^[@ref2],[@ref3]^ Adenocarcinoma, which is the majority type of Ampullary carcinoma is predominantly of the intestinal (47 percent) or pancreato-biliary (24 percent) histologic subtypes.^[@ref4]^ Interestingly, histologic and histo-molecular phenotypes are important prognostic variables.^[@ref5]^ For example, histo-molecular pancreato-biliary phenotype (CDX- negative, MUC 1-positive) has a poor prognosis when compared to intestinal phenotype (CDX- positive MUC 1-negative).^[@ref5]^ This understanding might help in making treatment decisions, particularly when using adjuvant therapy. Also, the lymph node status around disease onset is another important prognostic factor. There is no well-framed set of guidelines on when to use adjuvant therapy because of the relative infrequency of disease and paucity of robust clinical studies. Here we try to give an outline of the current treatment strategies and the molecular alterations with their actionable targets specific to Ampullary Carcinoma.

Staging and survival of ampullary carcinoma {#sec1-2}
===========================================

Approximately fifty percent of patients with Ampullary Carcinoma presents at an advanced stage^[@ref6]^ with the stage at the diagnosis being the critical prognostic factor.^[@ref7]^ For those who present at an early stage, standard treatment has been complete surgical resection via pancreaticoduodenectomy. However, because the disease presents in older age groups and the risks of surgical resection, approximately only 40 percent of the patients undergo surgical resection.^[@ref8]^ This understanding has led to the usage of other surgical approaches like endoscopic papillectomy^[@ref9]^ and trans-duodenal local resection.^[@ref10]^ The above procedures, in contrast to pancreaticoduodenectomy, have lesser peri-operative morbidity and mortality. ^[@ref11]^ Nevertheless, these interventions have the drawback of patients having poor resection margins and higher chances of recurrence.^[@ref11]^

Even though the likelihood of successful resection is higher in early-stage disease, approximately 45 percent of the treated population develops recurrence over time.^[@ref12]^ Therefore, a section of these patients could potentially get benefited from chemoradiation or chemotherapy.

Adjuvant therapy {#sec1-3}
================

Most of the evidence data for the use of concurrent chemoradiation in Ampullary Carcinoma is based on retrospective analyses reported from large academic institutions (Table 1^[@ref12]^). A retrospective study at Mayo clinic reported likely benefit with concurrent radiotherapy and 5-fluorouracil 5-FU) chemotherapy following Pancreaticoduodenectomy. However, an improvement in overall survival (median 3.4 years *vs* 1.6 years) was only demonstrated among patients with positive lymph nodes. This study could not confirm the clinical benefit in patients with negative lymph node status, thereby signifying the role of lymph node status as a crucial predictor of outcome.^[@ref13]^ In a study from Duke university, Palta *et al*., showed significant enhancement in three-year local control (88% *vs* 55%, P=0.001) with an inclination toward improved overall survival (62% *vs* 46%, P=0.074) and recurrence-free survival (66% *vs* 48%, P=0.09) with addition of adjuvant chemoradiation over surgery alone.^[@ref14]^ In addition, 28% of patients who received neoadjuvant chemoradiation for inoperable tumors also showed pathological complete response status. Another recent retrospective study by Krishnan *et al*., illustrated a notable clinical benefit with chemoradiation when compared to surgery alone among patients with T3/T4 or lymph node (LN) positive disease, with a predilection toward a better overall survival (35.2 *vs* 16.5 months; P=0.06).^[@ref15]^ Enhanced overall survival on using adjuvant chemoradiation in patients with positive LN has also been reported.^[@ref16]^ Furthermore, another retrospective study by Mehta *et al*., showed significant clinical benefit with chemoradiation among patients with large tumor size or positive LNs.^[@ref16]^

Contrary to the above, few studies have shown a lack of notable advantage on using adjuvant chemoradiation regardless of the LN status and tumor stage. In a single-center retrospective study by Zhou *et al*., a significant benefit with chemoradiation was not demonstrated, though there was no substantial improvement in median overall survival (OS) (33.4 *vs* 36.2 months) among patients with positive LN.^[@ref17]^ In another study, 104 patients with aggressive features such as positive lymph nodes, pancreatic infiltration or poor differentiation were either treated with adjuvant chemoradiation (49 patients) or observed due to poor performance status, postoperative complications or patient refusal. The results showed no impact of adjuvant chemoradiation on overall survival or locoregional recurrences.^[@ref12]^ Most recently, a single center retrospective study on 54 patients with ampullary carcinoma did not show any significant difference in overall survival and progression free survival with either CRT (5 patients) or chemotherapy (13 patients) *vs* surgery alone (27 patients).^[@ref18]^ However, in this study, sample size is small and the patients who received adjuvant therapy were found to have an advanced stage of disease.^[@ref18]^ The frequently quoted prospective randomized EORTC trial, examining the role of adjuvant chemoradiation, analyzed pancreatic, and peri-ampullary carcinomas separately. However, Ampullary Carcinomas were grouped along with other peri-ampullary carcinomas, making it any meaningful interpretation difficult.^[@ref19]^ In conclusion, there exists an unmet need for a randomized controlled trial as all currently available information on chemoradiation in Ampullary Carcinoma is retrospective in nature and all such analyses are beset with possible selection biases. However, drawing from available information, most centers currently consider chemoradiation for inoperable, incompletely resected or large tumors or patients with positive LN.

###### 

Studies on adjuvant chemoradiotherapy.

  Author                        N                                Type of Malignancy                     Treatment group                                          Treatment group protocol                                       Control group        Response                                                                                           Benefit                                                                                                  Study Design
  ----------------------------- -------------------------------- -------------------------------------- -------------------------------------------------------- -------------------------------------------------------------- -------------------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------
  Bhatia^[@ref13]^              125                              Ampullary Carcinoma                    Chemoradiation n=29                                      RT 50.4 Gy with concurrent 5-FU                                Only surgery n=96    OS 3.4 yr vs 1.6 yr in those with positive LN status                                               Yes (if node +ve)                                                                                        Retrospective
  Sikora^[@ref12]^              113 (104 alive r afte surgery)   Ampullary Carcinoma                    Chemoradiation n=49                                      RT 50.4 Gy with concurrent 5-FU                                Only surgery n=55    No significant OS and median survival difference                                                   No                                                                                                       Retrospective
  Palta^[@ref14]^               137                              Ampullary Carcinoma                    Chemoradiation Adjuvant n=43                             RT 50.4 Gy with concurrent Chemotherapy                        Only surgery n=76    LC 88% vs 55%,                                                                                     Yes                                                                                                      Retrospective
  Lee^[@ref20]^                 39                               Ampullary Carcinoma                    Chemoradiation n=13                                      RT 48.7 Gy with concurrent 5-FU                                Only surgery n=26    OS 55% DFS 54%                                                                                     Yes (if node +ve)                                                                                        Retrospective
  Krishnan^[@ref15]^            96                               Ampullary Carcinoma                    Chemoradiation n=54                                      RT 50.4 Gy with concurrent 5-FU (52%) and Cepacetabine (43%)   Only surgery n=42    35.2 months with CRT vs 16.5 months with only surgery                                              Yes (if T3/T4)                                                                                           Retrospective
  Kim^[@ref21]^                 118                              Ampullary Carcinoma                    Chemoradiation n=41                                      RT 40 Gy with 5-FU split course                                Only surgery n=77    mproved LC in ICRT group                                                                           Yes (especially if node +ve)                                                                             Retrospective
  Narang^[@ref22]^              186                              Ampullary Carcinoma                    Chemoradiation n=66                                      RT median dose 50.4 Gy with 5-FU                               Only surgery n=120   Median OS 39.9 months                                                                              Yes (if node +ve)                                                                                        Retrospective
  Zhou^[@ref17]^                111                              Ampullary Carcinoma                    Chemoradiation n=50                                      Rt median dose 50.4 Gy with 5-FU or Capecitabine               Only surgery n=61    33.4 months median OS with CRT vs 36.2 months with surgery alone (not statistically significant)   No                                                                                                       Retrospective
  Willet^[@ref23]^              17 (high risk features           Ampullary Carcinoma at presentation)   Radiation n=12                                           na                                                             Only surgery n=5     Improved local control (not statistically significant)                                             No                                                                                                       Retrospective
  Mehta                         na                               Ampullary Carcinoma                    Chemoradiation n=12 (patients with high risk features)   RT median dose 45 Gy with 5-FU                                 na                   Median survival 34 months and Actuarial Overall survival 89%                                       Yes (if +ve LN status, large tumor size, poor histology, neurovascular invasion)                         Retrospective
  Al-Jumayli et al.^[@ref18]^   45                               Ampullary Carcinoma                    Chemoradiation n=5 Chemotherapy n=13                     na                                                             Only surgery n=27    Median overall survival of the cohort is 30 months                                                 No statistically significant difference in PFS and OS between the surgery vs CRT or chemotherapy group   Singleet center retrospective

Role of chemotherapy in advanced ampullary carcinoma {#sec1-4}
====================================================

Chemotherapy does a pivotal job in the treatment of Ampullary Carcinoma, especially in patients who present with distant metastasis/ recurrence or unresectable locally advanced disease (Table 2^[@ref24]^). A retrospective study has reported the use of chemotherapy for 12 patients having advanced Ampullary Carcinoma and 14 patients having recurrent Ampullary Carcinoma. In this study, patients received either 5-FU based regimen or Gemcitabine-based regimen. The patients had poor treatment outcome with progression- free survival of 2.5 and 3.5 months in 5-FU and Gemcitabine group, respectively.^[@ref24]^ Apart from the conventional 5-FU or Gemcitabine-based regimen, a study has substantiated usage of XELOX regimen (Oxaliplatin and Capecitabine combined). In this study, 21 patients who were affected by recurrent or metastatic Ampullary Carcinoma were given XELOX regimen and reevaluated over 16.6 months. 7.6 months and 19.7 months were the median time to progression (TTP) and median overall survival (OS), respectively. Also, there was statistically significant longer TTP in intestinal phenotype when compared to pancreatobiliary phenotype. ^[@ref25]^ Similarly, a phase-II study has delineated the usage of CAPOX (Capecitabine and Oxaliplatin combined) regimen in 30 patients with either advanced Ampullary or small bowel carcinoma. 11.3 months and 20.4 months were the median TTP and median OS, respectively.^[@ref26]^ Recently, a case report has also demonstrated a good response to 5-FU in a patient with advanced ampullary adenocarcinoma.^[@ref27]^

A retrospective study compiling the data from National cancer database has shown the overall benefit of using adjuvant chemotherapy in patients who underwent pancreatoduodenectomy when compared to observation alone.^[@ref28]^ Similarly, ESPAC-3 periampullary cancer trial has showed the advantage of using adjuvant chemotherapy after surgical resection when compared to observation alone. However, only patients with poor prognostic variables like poor tumor differentiation and positive lymph node status have had this advantage.^[@ref29]^ Furthermore, a study analyzed 29 patients with advanced Ampullary Carcinoma who were either treated with Cisplatin plus 5-FU or Cisplatin plus Gemcitabine. 4.9 months and 12.5 months were the median TTP and median OS with only a little difference between the two regimens.^[@ref30]^

###### 

Studies on using chemotherapy alone.

  Author                        N                                                                        Type of malignancy                            Treatment regimen                           Response                                                            Study design
  ----------------------------- ------------------------------------------------------------------------ --------------------------------------------- ------------------------------------------- ------------------------------------------------------------------- ---------------
  Shoji *et al.*.^[@ref24]^     26 (advanced ampullar carcinoma n=12, recurrent ampullary cancer n=14)   Ampullary Carcinoma                           5-FU based vs Gemcitabine based             Median OS 9.1 months. Median progression free survival 3.2 months   Retrospective
  Senatore *et al.*^[@ref27]^   na                                                                       Ampullary Carcinoma                           5-FU based                                  Good response                                                       Case report
  Kim HS *et al.*.^[@ref25]^    21                                                                       Recurrent or metastatic Ampullary Carcinoma   Capecitabine + Oxaliplatin                  Median OS 19.7 months Median TTP 7.6 months                         Retrospective
  Overman *et al.*^[@ref26]^    30                                                                       Ampullary+ Small bowel carcinoma              Capecitabine+ Oxaliplatin                   Median OS 20.4 months. Median TTP 11.3 months                       Phase II
  Nassour *et al.*^[@ref28]^    880                                                                      Ampullary Carcinoma                           Na                                          Median OS 47.2 months Good response                                 Retrospective
  Neoptolemos et                428                                                                      Ampullary+ Bileduct+ other cancers            5-FU and Gemcitabine groups                 Median OS 43.1 months                                               Phase III RCT
  Kim ST *et al.*^[@ref30]^     29                                                                       Ampullary Carcinoma                           Cisplatin+ Gemcitabine/ 5-FU/Capecitabine   Median OS 12.5 months Median TTP 4.9 months                         Phase II
  Cereda *et al.*^[@ref31]^     37                                                                       Biliary tract+ Ampullary Carcinoma            Cisplatin+ Epirubicin+ Gemcitabine+ 5-FU.   Median OS 12.1 months Median PFS 7.9 months                         Phase II
  Andre *et al.*^[@ref32]^      56                                                                       Biliary tract + Ampullary Carcinoma           Gemcitabine + Oxaliplatin                   Median OS 7.6-15.4 months                                           Phase II
  Gibson *et al.*^[@ref33]^     38                                                                       Small Bowel+ Ampullary Carcinoma              5FU+Doxorubicin+ Mitomycin                  Median OS 8 months.                                                 Phase II
  Valle *et al.*^[@ref34]^      410                                                                      Biliary tract + Ampullary Carcinoma           Gemcitabine+ Cisplatin                      Median OS 11.7 months.                                              Phase III

Molecular alterations in ampullary carcinoma {#sec1-5}
============================================

As discussed earlier, histologic and histo-molecular phenotypes are important prognostic factors. However, as Ampullary Carcinoma emerges from an anatomical site where three different epithelia intestinal/pancreatic ductal/biliary converge defining its histomorphology is susceptible to interobserver variability, which reduces the prognostic reliability.^[@ref35]^ So recently, molecular landscape and mutations involving Ampullary Carcinoma have been brought up into clinical practice for better defining the prognosis, response to treatment, and finding the actionable targets.

Chromosomal alterations were the first molecular alterations described in various studies on the genetic landscape of Ampullary carcinoma. To start with, a study has shown that chromosome 5q loss of heterozygosity as one of the foremost events in the evolution of Ampullary Carcinoma.^[@ref36]^ Similarly, another study has shown a chromosome 17p loss as an indication for poor prognosis and helps to decide if the patients need adjuvant therapy in addition to surgery.^[@ref37]^ Furthermore, molecular alterations involving the genes TP53, K-RAS, APC, ELF-3,^[@ref38]^ have been increasingly identified in Ampullary Carcinoma.^[@ref35]^ Studies have shown that APC gene is a frequently mutated gene in the intestinal subgroup of Ampullary Carcinoma, in contrast to pancreatobiliary type where there is a predominant presence of TP53 and K-RAS mutations.^[@ref35]^ Even though certain genetic alterations are more often found in specific histological types of Ampullary Carcinoma, there is still a huge heterogeneity between morphologic and molecular levels.

In addition to the above, molecular alterations involving the WNT, PI3K, and ERBB2 have also been described.^[@ref39]^ Recently, Pinto *et al.* and Mandelker *et al.* described pathogenic germline alteration (PGA) involving BRCA2 gene in Ampullary Carcinoma.^[@ref40],[@ref41]^ Also, germline alterations involving ATM, RAD50, and somatic alterations involving BRAF and ELF3 have been identified most recently.^[@ref42]^ Applying the molecular profile of Ampullary Carcinoma toward better defining the prognosis and finding actionable therapeutic targets is gaining importance. For example, P53 and K-RAS mutations have been identified as poor prognostic factors.^[@ref43]^ Moreover, the presence of BRCA2 and ATM mutations in Ampullary Carcinoma gives an opportunity to synthetically target the tumor cells with platinum agents and poly ADP(adenosine diphosphate-ribose) polymerase (PARP) inhibitors.^[@ref42]^ In a similar fashion, trastuzumab and PD-L1 inhibition could be used in patients with mutations involving ERBB2 amplification and DNA mismatch repair, respectively.^[@ref42]^

Conclusions {#sec1-6}
===========

In conclusion, chemoradiotherapy plays a crucial role in early Ampullary Carcinoma after surgical resection, especially in nodepositive disease. In contrast, few studies have shown no meaningful benefit of chemoradiation irrespective of node status and tumor stage. Nevertheless, chemoradiation should be considered in patients with poor prognostic factors given the high risk of recurrence and local failure with surgery alone. For advanced tumors, owing to the rarity of these tumors, currently, the data is limited on the choice of a chemo regimen. Therefore no consensus regarding optimal management as these tumors were assessed in combined series including pancreatic and small bowel cancers. Treatment with a combination of gemcitabine and cisplatin or treating in lines of pancreatic cancer seems reasonable. Also combining molecular data with histomorphology may define the prognosis and aid in treatment selection.
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